Table 1 Characteristics of study participants
Study (year) | Intervention/Control | Age year ± SD | Female n (%) | Type of BD I/II n (%) | Phase of BD | Onset age year ± SD | Rapid cycler n (%) | Taking mood stabilizer n (%) |
|---|---|---|---|---|---|---|---|---|
van der Loos (2009) | Intervention: 64 LTG | 45.2 ± 12.1 | 37/64 (57.8) | I: 43 (67.2) II: 21 (32.8) | MDE | ND | 12/64 (18.8) | Li: 64 (100) |
Control: 60 Placebo | 47.6 ± 11.6 | 30/60 (50.0) | I: 41 (68.3) II: 19 (31.7) | MDE | ND | 4/64 (6.7) | Li: 60 (100) | |
Houston (2009) | Intervention: 101 Olanzapine | 38.6 ± 11.2 | 61/101 (60.4) | I: 101 (100) | MD | ND | 27/101 (26.7) | VPA: 101 (100) |
Control: 101 Placebo | 38.5 ± 11.1 | 58/101 (57.4) | I: 101 (100) | MD | ND | 22/101 (21.8) | VPA: 101 (100) | |
Sachs (2011) | Intervention: 148 Ziprasidone | 40.4 ± 11.4 | 89/147 (60.5) | I: 148 (100) | MDE | ND | ND | Li: 53 (36.3) VPA: 52 (35.6) LTG: 41 (28.1) |
Control: 150 Placebo | 40.4 ± 11.9 | 91/147 (61.9) | I: 150 (100) | MDE | ND | ND | Li: 54 (36.7) VPA: 52 (35.4) LTG: 41 (27.9) | |
Loebel (2014) | Intervention: 183 Lurasidone | 41.0 ± 11.5 | 86/179 (48.0) | I: 183 (100) | MDE | 28.1 ± 11.0 | ND | Li: 90 (50.3) VPA: 89 (49.7) |
Control: 165 Placebo | 42.6 ± 11.8 | 76/161 (47.2) | I: 165 (100) | MDE | 29.5 ± 10.7 | ND | Li: 73 (45.6) VPA: 87 (54.4) | |
Suppes (2016) | Intervention: 180 Lurasidone | 43.1 ± 11.9 | 91/176 (51.7) | I: 180 (100) | MDE | 28.8 ± 12.1 | 32/176 (18.2) | Li: 56 (31.8) VPA: 120 (68.2) |
Control: 176 Placebo | 44.1 ± 12.0 | 93/166 (56.0) | I: 176 (100) | MDE | 29.8 ± 12.8 | 21/166 (12.7) | Li: 57 (34.3) VPA: 109 (65.7) |